Get the Stockscreener App
1.13
4.24%
-0.05
Pre-market:
1.20
0.07
+6.19%
Fibrobiologics Inc stock is traded at $1.13, with a volume of 210.13K.
It is down -4.24% in the last 24 hours and down -37.57% over the past month.
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
See More
Previous Close:
$1.18
Open:
$1.2
24h Volume:
210.13K
Relative Volume:
1.08
Market Cap:
$7.86M
Revenue:
-
Net Income/Loss:
$-18.68M
P/E Ratio:
-0.1528
EPS:
-7.3948
Net Cash Flow:
$-15.70M
1W Performance:
-13.74%
1M Performance:
-37.57%
6M Performance:
-17.52%
1Y Performance:
-89.73%
1-Day Range:
$1.12
$1.23
1-Week Range:
$1.10
$1.40
52-Week Range:
$0.6201
$11.40
Fibrobiologics Inc Stock (FBLG) Company Profile
Name
Fibrobiologics Inc
Sector
Industry
Phone
281-671-5150
Address
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
1.13 | 9.67M | 0 | -18.68M | -15.70M | -7.3948 |
VRTX
Vertex Pharmaceuticals Inc
|
502.31 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
738.72 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
187.46 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
930.52 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.87 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-24 | Initiated | H.C. Wainwright | Buy |
| Sep-24-24 | Initiated | Maxim Group | Buy |
Fibrobiologics Inc Stock (FBLG) Latest News
FibroBiologics receives European patent for fibroblast therapy - Investing.com
FibroBiologics, Inc. (FBLG) Stock Price, News, Quote & History - Yahoo! Finance Canada
FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity - Morningstar
Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - Eagle-Tribune
FibroBiologics (FBLG) Slips 4.90% to $1.36 as Shares Drift Toward Key SupportVanna Flow - dars.gov.et
FibroBiologics Shareholders Approve Potential Warrant-Driven Share Issuance - TipRanks
FibroBiologics (NASDAQ: FBLG) raises $0.5M in insider deal - Stock Titan
Hamid Khoja Discloses Investment at FibroBiologics with 7.5% Stake - TradingView
Private deal gives FibroBiologics (FBLG) CSO hundreds of thousands of shares - Stock Titan
FBLG: Shareholders approved new share issuances as clinical and strategic progress was highlighted - tradingview.com
FibroBiologics CSO invests $500,000 in private placement By Investing.com - Investing.com
FibroBiologics, Inc. (NASDAQ:FBLG) CSO Invests ~$0.5M in Private Placement With Warrants - TradingView
Fibrobiologics Announces Closing of $0.5 Mill - Moomoo
FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer - PR Newswire
FibroBiologics (FBLG) turns to a private stock-and-warrant deal for new funding - Stock Titan
Form 8K Fibrobiologics Inc For: 15 September By Investing.com - Investing.com Nigeria
FibroBiologics Announces Insider Private Placement Financing - TipRanks
FibroBiologics (FBLG) CSO to buy new shares and warrants in private deal - Stock Titan
Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications - ACCESS Newswire
FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing - Yahoo Finance
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media - Morningstar
A new patent covers a way to promote repair in damaged spinal discs from FibroBiologics. - Stock Titan
About 80% of Americans experience lower back pain. FibroBiologics gets a European patent. - Stock Titan
FibroBiologics ships new batch of diabetic ulce... - Pluang
FibroBiologics ships third batch of trial drug to Australia - Investing.com
FibroBiologics ships third batch of trial drug to Australia By Investing.com - Investing.com India
FibroBiologics ships a third batch of wound treatment being tested to Australia - Stock Titan
FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial - PR Newswire
FibroBiologics regains Nasdaq bid price compliance - Investing.com
FibroBiologics Regains Compliance with Nasdaq Trading Rules - PR Newswire
FibroBiologics Adds Sports Agent Leigh Steinberg to Board of Directors - citybiz
FibroBiologics appoints Leigh Steinberg to board By Investing.com - Investing.com Canada
Leigh Steinberg, agent behind $4B in deals, joins FibroBiologics (FBLG) board - Stock Titan
FibroBiologics | 10-Q: Q1 2026 Earnings Report - Moomoo
FibroBiologics receives Australian patent for disc disease therapy By Investing.com - Investing.com Canada
FibroBiologics receives Australian patent for disc disease therapy - Investing.com
FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease - Morningstar
FibroBiologics Says Preclinical Data Shapes Design of Further Studies for Degenerative Joint Treatment - Sahm
FibroBiologics reports cartilage repair in animal study By Investing.com - Investing.com South Africa
FibroBiologics reports cartilage repair in animal study - Investing.com
FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints - PR Newswire
Armistice Capital discloses 9.99% FibroBiologics (FBLG) stake via Master Fund - Stock Titan
FibroBiologics Inc - Smartkarma
FBLG Q2 2026 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Biotech Advances Fibroblast Pipeline - vinanet.vn
FBLG Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 7.77% Share GainFinal Results - dars.gov.et
FibroBiologics receives patent for islet transplant method By Investing.com - Investing.com UK
FibroBiologics receives patent for islet transplant method - Investing.com
Fibrobiologics Granted US Patent Covering The Use Of Fibroblasts - TradingView
FibroBiologics Patent Could Help Stretch Scarce Donor Pancreases - Stock Titan
FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets - PR Newswire
FBLG Q2 2026 Earnings: Narrower Loss Beats Estimates as Pipeline AdvancesEPS Guidance Update - dars.gov.et
Fibrobiologics Inc Stock (FBLG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fibrobiologics Inc Stock (FBLG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 03 '26 |
Buy |
0.41 |
18,200 |
7,373 |
5,942,275 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 02 '26 |
Buy |
0.35 |
17,428 |
6,152 |
5,924,075 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 04 '26 |
Buy |
0.38 |
15,872 |
6,006 |
5,958,147 |
| Davis Jason | Chief Financial Officer |
Mar 02 '26 |
Buy |
0.41 |
70,000 |
28,973 |
70,000 |
| GARCIA RUBEN A | General Counsel |
Feb 27 '26 |
Buy |
0.33 |
40,000 |
13,056 |
180,000 |
| GARCIA RUBEN A | General Counsel |
Dec 11 '25 |
Buy |
0.34 |
140,000 |
47,600 |
140,000 |
1.96%
1.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):